JP2020506899A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506899A5 JP2020506899A5 JP2019538407A JP2019538407A JP2020506899A5 JP 2020506899 A5 JP2020506899 A5 JP 2020506899A5 JP 2019538407 A JP2019538407 A JP 2019538407A JP 2019538407 A JP2019538407 A JP 2019538407A JP 2020506899 A5 JP2020506899 A5 JP 2020506899A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- disease
- acceptable salt
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- -1 [4- (trifluoromethyl) -1H-pyrazole-1-yl] methyl- Chemical group 0.000 claims 52
- 125000000217 alkyl group Chemical group 0.000 claims 31
- 150000001875 compounds Chemical class 0.000 claims 31
- 150000003839 salts Chemical class 0.000 claims 25
- 208000002193 Pain Diseases 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 150000002367 halogens Chemical class 0.000 claims 11
- 201000001119 neuropathy Diseases 0.000 claims 10
- 230000007823 neuropathy Effects 0.000 claims 10
- 208000033808 peripheral neuropathy Diseases 0.000 claims 10
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 9
- 125000003545 alkoxy group Chemical group 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 208000011580 syndromic disease Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 8
- 125000001424 substituent group Chemical group 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 6
- 208000010877 cognitive disease Diseases 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims 4
- 210000003169 central nervous system Anatomy 0.000 claims 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims 4
- 125000001188 haloalkyl group Chemical group 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 3
- 206010020751 Hypersensitivity Diseases 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 206010028813 Nausea Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 201000002661 Spondylitis Diseases 0.000 claims 3
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 3
- 206010047700 Vomiting Diseases 0.000 claims 3
- 208000026935 allergic disease Diseases 0.000 claims 3
- 230000001684 chronic effect Effects 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 230000009610 hypersensitivity Effects 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 230000008693 nausea Effects 0.000 claims 3
- 201000008482 osteoarthritis Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 230000008673 vomiting Effects 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 2
- 208000008930 Low Back Pain Diseases 0.000 claims 2
- 102100029814 Monoglyceride lipase Human genes 0.000 claims 2
- 101710116393 Monoglyceride lipase Proteins 0.000 claims 2
- 206010034912 Phobia Diseases 0.000 claims 2
- 208000026301 Postoperative Cognitive Complications Diseases 0.000 claims 2
- 208000004078 Snake Bites Diseases 0.000 claims 2
- 208000029033 Spinal Cord disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 206010048010 Withdrawal syndrome Diseases 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 206010004398 benign neoplasm of skin Diseases 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 208000010247 contact dermatitis Diseases 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 201000003146 cystitis Diseases 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 208000028867 ischemia Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 230000010410 reperfusion Effects 0.000 claims 2
- 206010039083 rhinitis Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 210000004500 stellate cell Anatomy 0.000 claims 2
- 230000009529 traumatic brain injury Effects 0.000 claims 2
- 208000019206 urinary tract infection Diseases 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 208000007788 Acute Liver Failure Diseases 0.000 claims 1
- 206010000804 Acute hepatic failure Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010053164 Alcohol withdrawal syndrome Diseases 0.000 claims 1
- 208000003130 Alcoholic Neuropathy Diseases 0.000 claims 1
- 208000006820 Arthralgia Diseases 0.000 claims 1
- 208000036640 Asperger disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000004020 Brain Abscess Diseases 0.000 claims 1
- 206010048962 Brain oedema Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 206010006784 Burning sensation Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 208000001387 Causalgia Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 206010008479 Chest Pain Diseases 0.000 claims 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000000094 Chronic Pain Diseases 0.000 claims 1
- 208000036166 Classic glucose transporter type 1 deficiency syndrome Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 claims 1
- 206010011732 Cyst Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 208000010772 Dog disease Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 206010013754 Drug withdrawal syndrome Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 208000004232 Enteritis Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000009139 Gilbert Disease Diseases 0.000 claims 1
- 208000022412 Gilbert syndrome Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010018341 Gliosis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 108700006771 Glut1 Deficiency Syndrome Proteins 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000018565 Hemochromatosis Diseases 0.000 claims 1
- 208000032843 Hemorrhage Diseases 0.000 claims 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims 1
- 206010056328 Hepatic ischaemia Diseases 0.000 claims 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000006877 Insect Bites and Stings Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 206010065973 Iron Overload Diseases 0.000 claims 1
- 208000032382 Ischaemic stroke Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000034800 Leukoencephalopathies Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000019430 Motor disease Diseases 0.000 claims 1
- 208000003423 Mucocele Diseases 0.000 claims 1
- 206010028116 Mucosal inflammation Diseases 0.000 claims 1
- 201000010927 Mucositis Diseases 0.000 claims 1
- 208000023178 Musculoskeletal disease Diseases 0.000 claims 1
- 206010029240 Neuritis Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 1
- 206010029279 Neurogenic bladder Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 201000010133 Oligodendroglioma Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 claims 1
- 201000007100 Pharyngitis Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 1
- 206010037423 Pulmonary oedema Diseases 0.000 claims 1
- 206010037660 Pyrexia Diseases 0.000 claims 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 claims 1
- 206010061481 Renal injury Diseases 0.000 claims 1
- 206010063897 Renal ischaemia Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 208000003589 Spider Bites Diseases 0.000 claims 1
- 206010042496 Sunburn Diseases 0.000 claims 1
- 208000000491 Tendinopathy Diseases 0.000 claims 1
- 206010043255 Tendonitis Diseases 0.000 claims 1
- 206010043269 Tension headache Diseases 0.000 claims 1
- 208000008548 Tension-Type Headache Diseases 0.000 claims 1
- 208000010641 Tooth disease Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 208000018839 Wilson disease Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- DSSDRIRIOUDLOP-VXGBXAGGSA-N [(2R)-1,1,1-trifluoro-3-hydroxypropan-2-yl] (3R)-3-(4-fluoropyrazol-1-yl)-1-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound FC=1C=NN(C=1)[C@H]1COC2(C1)CCN(CC2)C(=O)O[C@@H](C(F)(F)F)CO DSSDRIRIOUDLOP-VXGBXAGGSA-N 0.000 claims 1
- YOOFATDARIZRHU-HZPDHXFCSA-N [(2R)-1,1,1-trifluoro-3-hydroxypropan-2-yl] (3S)-3-(3-cyanophenyl)-1-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound C(#N)C=1C=C(C=CC=1)[C@H]1COC2(C1)CCN(CC2)C(=O)O[C@@H](C(F)(F)F)CO YOOFATDARIZRHU-HZPDHXFCSA-N 0.000 claims 1
- QHTCZIZAZAKICD-OAHLLOKOSA-N [(2R)-1,1,1-trifluoro-3-hydroxypropan-2-yl] 2-(4-cyclopropylpyrazol-1-yl)-7-azaspiro[3.5]nonane-7-carboxylate Chemical compound C1(CC1)C=1C=NN(C=1)C1CC2(C1)CCN(CC2)C(=O)O[C@@H](C(F)(F)F)CO QHTCZIZAZAKICD-OAHLLOKOSA-N 0.000 claims 1
- QEIVLYABILPMFS-CQSZACIVSA-N [(2R)-1,1,1-trifluoro-3-hydroxypropan-2-yl] 2-[6-(difluoromethyl)pyridin-3-yl]oxy-7-azaspiro[3.5]nonane-7-carboxylate Chemical compound FC(C1=CC=C(C=N1)OC1CC2(C1)CCN(CC2)C(=O)O[C@@H](C(F)(F)F)CO)F QEIVLYABILPMFS-CQSZACIVSA-N 0.000 claims 1
- CGUGZDYEJHAHQJ-FQNRMIAFSA-N [(2R)-1,1,1-trifluoro-3-hydroxypropan-2-yl] 3-(5-cyano-2-fluorophenyl)-1-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound C(#N)C=1C=CC(=C(C=1)C1COC2(C1)CCN(CC2)C(=O)O[C@@H](C(F)(F)F)CO)F CGUGZDYEJHAHQJ-FQNRMIAFSA-N 0.000 claims 1
- GUJLBVCPMOJSKZ-TYZXPVIJSA-N [(2R)-1,1,1-trifluoro-3-hydroxypropan-2-yl] 3-[4-(difluoromethyl)pyridin-2-yl]-1-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound FC(C1=CC(=NC=C1)C1COC2(C1)CCN(CC2)C(=O)O[C@@H](C(F)(F)F)CO)F GUJLBVCPMOJSKZ-TYZXPVIJSA-N 0.000 claims 1
- UONRZOZCBWRSGO-PIJUOVFKSA-N [(2R)-1,1,1-trifluoro-3-hydroxypropan-2-yl] 3-[4-(trifluoromethyl)pyrazol-1-yl]-1-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound FC(C=1C=NN(C=1)C1COC2(C1)CCN(CC2)C(=O)O[C@@H](C(F)(F)F)CO)(F)F UONRZOZCBWRSGO-PIJUOVFKSA-N 0.000 claims 1
- KUCXZEKRZNHGAX-SBXXRYSUSA-N [(2R)-1,1,1-trifluoro-3-hydroxypropan-2-yl] 3-[6-(trifluoromethyl)pyridin-2-yl]-1-oxa-8-azaspiro[4.5]decane-8-carboxylate Chemical compound FC(C1=CC=CC(=N1)C1COC2(C1)CCN(CC2)C(=O)O[C@@H](C(F)(F)F)CO)(F)F KUCXZEKRZNHGAX-SBXXRYSUSA-N 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 231100000836 acute liver failure Toxicity 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 208000026345 acute stress disease Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000029650 alcohol withdrawal Diseases 0.000 claims 1
- 208000020701 alcoholic polyneuropathy Diseases 0.000 claims 1
- 125000005466 alkylenyl group Chemical group 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000004596 appetite loss Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 208000006752 brain edema Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 206010008129 cerebral palsy Diseases 0.000 claims 1
- 201000001352 cholecystitis Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 claims 1
- 208000031513 cyst Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000003210 demyelinating effect Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 1
- WJJMNDUMQPNECX-UHFFFAOYSA-N dipicolinic acid Chemical compound OC(=O)C1=CC=CC(C(O)=O)=N1 WJJMNDUMQPNECX-UHFFFAOYSA-N 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 230000004406 elevated intraocular pressure Effects 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 208000026663 encephalopathy due to GLUT1 deficiency Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000010932 epithelial neoplasm Diseases 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 230000002964 excitative effect Effects 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 230000002489 hematologic effect Effects 0.000 claims 1
- 208000007475 hemolytic anemia Diseases 0.000 claims 1
- 231100000234 hepatic damage Toxicity 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 230000007803 itching Effects 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 208000037806 kidney injury Diseases 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 208000036546 leukodystrophy Diseases 0.000 claims 1
- 230000008818 liver damage Effects 0.000 claims 1
- 208000026320 liver hemangioma Diseases 0.000 claims 1
- 235000021266 loss of appetite Nutrition 0.000 claims 1
- 208000019017 loss of appetite Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000000938 luteal effect Effects 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 240000004308 marijuana Species 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 208000018389 neoplasm of cerebral hemisphere Diseases 0.000 claims 1
- 208000023833 nerve sheath neoplasm Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000008795 neuromyelitis optica Diseases 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 201000005528 peripheral nervous system neoplasm Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 230000007096 poisonous effect Effects 0.000 claims 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 208000005333 pulmonary edema Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 208000007771 sciatic neuropathy Diseases 0.000 claims 1
- 208000010157 sclerosing cholangitis Diseases 0.000 claims 1
- 210000004706 scrotum Anatomy 0.000 claims 1
- 201000009890 sinusitis Diseases 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 201000001716 specific phobia Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 201000004415 tendinitis Diseases 0.000 claims 1
- 230000001256 tonic effect Effects 0.000 claims 1
- 208000004371 toothache Diseases 0.000 claims 1
- 231100000331 toxic Toxicity 0.000 claims 1
- 230000002588 toxic effect Effects 0.000 claims 1
- 231100000419 toxicity Toxicity 0.000 claims 1
- 230000001988 toxicity Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 208000009174 transverse myelitis Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 230000002861 ventricular Effects 0.000 claims 1
- 208000009935 visceral pain Diseases 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448498P | 2017-01-20 | 2017-01-20 | |
| US62/448,498 | 2017-01-20 | ||
| PCT/IB2018/050103 WO2018134695A1 (en) | 2017-01-20 | 2018-01-08 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as magl inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020506899A JP2020506899A (ja) | 2020-03-05 |
| JP2020506899A5 true JP2020506899A5 (enExample) | 2021-02-04 |
Family
ID=61168134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538407A Withdrawn JP2020506899A (ja) | 2017-01-20 | 2018-01-08 | Ｍａｇｌ阻害薬としての１，１，１−トリフルオロ−３−ヒドロキシプロパン−２−イルカルバマート誘導体 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10329308B2 (enExample) |
| EP (1) | EP3571191A1 (enExample) |
| JP (1) | JP2020506899A (enExample) |
| KR (1) | KR20190104405A (enExample) |
| CN (1) | CN110382479A (enExample) |
| AU (1) | AU2018208846A1 (enExample) |
| BR (1) | BR112019014688A2 (enExample) |
| CA (1) | CA3050625C (enExample) |
| IL (1) | IL267899A (enExample) |
| MX (1) | MX2019008626A (enExample) |
| RU (1) | RU2720203C1 (enExample) |
| SG (1) | SG11201906417RA (enExample) |
| TW (1) | TWI660946B (enExample) |
| WO (1) | WO2018134695A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1249101A1 (zh) | 2015-07-31 | 2018-10-26 | 辉瑞公司 | 作为magl抑制剂的1，1，1-三氟-3-羟基丙-2-基氨基甲酸酯衍生物及1，1，1-三氟-4-羟基丁-2-基氨基甲酸酯衍生物 |
| BR112019014688A2 (pt) | 2017-01-20 | 2020-02-18 | Pfizer Inc. | Derivados de carbamato de 1,1,1-trifluoro-3-hidroxipropan-2-il como inibidores de magl |
| US10662159B2 (en) * | 2017-11-22 | 2020-05-26 | Makscientific, Llc | ABHD6 and dual ABHD6/MGL inhibitors and their uses |
| WO2020152361A1 (en) * | 2019-01-25 | 2020-07-30 | NodThera Limited | Carbamate derivatives and uses thereof |
| MX2022011903A (es) * | 2020-03-26 | 2023-01-11 | Janssen Pharmaceutica Nv | Azaspirociclos como moduladores de monoacilglicerol lipasa. |
| PE20231215A1 (es) * | 2020-06-09 | 2023-08-17 | Pfizer | Compuestos espiro como antagonistas del receptor de melanocortina 4 y usos de los mismos |
| CA3192236A1 (en) | 2020-09-10 | 2022-03-17 | Tony Lahoutte | Antibody fragment against fap |
| IL301492A (en) | 2020-09-22 | 2023-05-01 | Janssen Pharmaceutica Nv | Cyclobutyl amide monoacylglycerol lipase modulators |
| WO2022135462A1 (zh) * | 2020-12-22 | 2022-06-30 | 鲁南制药集团股份有限公司 | Magl抑制剂的医药用途 |
| IL313987A (en) | 2021-12-29 | 2024-08-01 | Psy Therapeutics Inc | Inhibiting monoacylglycerol lipase (magl) |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| AU2023264245A1 (en) | 2022-05-02 | 2024-12-19 | Precirix N.V. | Pre-targeting |
| WO2024168426A1 (en) | 2023-02-13 | 2024-08-22 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
| CN116621792B (zh) * | 2023-05-16 | 2025-02-25 | 常州大学 | 一种制备n-正丁基-1,2-苯并异噻唑啉-3-酮-1-氧化物的方法 |
| CN118191332B (zh) * | 2024-03-19 | 2024-10-29 | 暨南大学 | 一种用于诊断术后认知功能障碍的血浆生物标志物及其应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0273659A1 (en) | 1986-12-27 | 1988-07-06 | Takeda Chemical Industries, Ltd. | Azaspiro compounds, their production and use |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| JPH10503768A (ja) | 1994-08-02 | 1998-04-07 | メルク シヤープ エンド ドーム リミテツド | アゼチジン、ピロリジンおよびピペリジン誘導体 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| AU3676100A (en) | 1999-04-09 | 2000-11-14 | Mochida Pharmaceutical Co., Ltd. | Remedies for neuropathic pain |
| BR0013085A (pt) | 1999-08-13 | 2002-04-23 | Aventis Cropscience Gmbh | Compostos espiro heterocìclicos como pesticidas |
| US20020151712A1 (en) | 1999-09-14 | 2002-10-17 | Nan-Horng Lin | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
| ES2279837T3 (es) | 2000-11-20 | 2007-09-01 | Scios Inc. | Inhibidores de tipo piperidina/piperazina de la quinasa p38. |
| EP1390372B1 (en) | 2001-05-14 | 2008-07-16 | F. Hoffmann-La Roche Ag | 1-oxa-3,9-diaza-spiro'5,5]undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor |
| US7825147B2 (en) | 2003-08-29 | 2010-11-02 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type-IV |
| SE0302811D0 (sv) | 2003-10-23 | 2003-10-23 | Astrazeneca Ab | Novel compounds |
| AR046756A1 (es) | 2003-12-12 | 2005-12-21 | Solvay Pharm Gmbh | Derivados de hidronopol como agonistas de receptores orl-1 humanos. |
| JP3912400B2 (ja) | 2004-03-30 | 2007-05-09 | 株式会社デンソー | 圧力センサ |
| ES2370788T3 (es) | 2005-02-07 | 2011-12-22 | Aerocrine Ab | Controlar flujo de aliento exhalado durante análisis. |
| EA013636B1 (ru) | 2005-05-25 | 2010-06-30 | Басф Акциенгезельшафт | Замещенные гетероароилом серин-амиды |
| EA013646B1 (ru) | 2005-05-25 | 2010-06-30 | Басф Акциенгезельшафт | Замещённые бензоилом серин-амиды |
| NZ564759A (en) | 2005-06-30 | 2011-08-26 | Prosidion Ltd | GPCR agonists |
| AR055395A1 (es) | 2005-08-26 | 2007-08-22 | Vertex Pharma | Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c |
| JP5290192B2 (ja) | 2006-12-05 | 2013-09-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | Ｍｃｈ−１に媒介される疾患における使用のための新規な置換されたジアザ−スピロ−ピリジノン誘導体 |
| FR2915198B1 (fr) | 2007-04-18 | 2009-12-18 | Sanofi Aventis | Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique. |
| MX2009011358A (es) | 2007-04-20 | 2009-11-05 | Schering Corp | Derivados de pirimidinona y metodos para su uso. |
| EP2058306A1 (en) | 2007-11-08 | 2009-05-13 | Schwarz Pharma Ag | Heteroaryl-substituted 2-pyridinyl-methylamine derivatives |
| MX2011000664A (es) | 2008-07-16 | 2011-02-24 | Schering Corp | Derivados biciclicos heterociclicos y uso de los mismos como moduladores de gpr119. |
| AU2009309988A1 (en) | 2008-10-29 | 2010-05-06 | Grunenthal Gmbh | Substituted spiroamines |
| US8772318B2 (en) | 2008-11-14 | 2014-07-08 | The Scripps Research Institute | Methods and compositions related to targeting monoacylglycerol lipase |
| TWI469979B (zh) * | 2008-12-24 | 2015-01-21 | Bial Portela & Ca Sa | 脂肪酸醯胺水解酶(faah)抑制劑、以及其藥學組成物與用途 |
| US8435977B2 (en) | 2009-04-22 | 2013-05-07 | Janssen Pharmaceutica, Nv | Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitors |
| AU2010239188B2 (en) | 2009-04-22 | 2016-03-31 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
| FR2945531A1 (fr) * | 2009-05-12 | 2010-11-19 | Sanofi Aventis | Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique |
| JPWO2011142359A1 (ja) | 2010-05-10 | 2013-07-22 | 日産化学工業株式会社 | スピロ化合物及びアディポネクチン受容体活性化薬 |
| FR2960875B1 (fr) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| AU2011307252B2 (en) | 2010-09-27 | 2015-06-25 | Janssen Pharmaceutica Nv | Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors |
| US8513423B2 (en) | 2010-10-22 | 2013-08-20 | Janssen Pharmaceutica, Nv | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors |
| CA2815353A1 (en) | 2010-10-22 | 2012-04-26 | Janssen Pharmaceutica Nv | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors |
| US8828996B2 (en) | 2011-03-14 | 2014-09-09 | Vertex Pharmaceuticals Incorporated | Morpholine-spirocyclic piperidine amides as modulators of ion channels |
| JP2014159376A (ja) | 2011-06-17 | 2014-09-04 | Taisho Pharmaceutical Co Ltd | アザスピロアルカン化合物 |
| MX350788B (es) | 2012-01-06 | 2017-09-13 | Abide Therapeutics Inc | Compuestos de carbamato y preparación y uso de los mismos. |
| WO2013131010A2 (en) | 2012-03-02 | 2013-09-06 | Icahn School Of Medicine At Mount Sinai | Function of chemokine receptor ccr8 in melanoma metastasis |
| WO2014012054A1 (en) | 2012-07-13 | 2014-01-16 | Pain Therapeutics, Inc. | Alzheimer's disease assay in a living patent |
| WO2014074715A1 (en) * | 2012-11-07 | 2014-05-15 | Genentech, Inc. | Cyclopropyl amide derivatives |
| MX2015017961A (es) * | 2013-07-03 | 2016-10-14 | Abide Therapeutics Inc | Compuestos orgánicos pirrolo-pirrol carbamato y relacionados, composiciones farmacéuticas y usos médicos de los mismos. |
| WO2016149401A2 (en) * | 2015-03-18 | 2016-09-22 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| HK1249101A1 (zh) | 2015-07-31 | 2018-10-26 | 辉瑞公司 | 作为magl抑制剂的1，1，1-三氟-3-羟基丙-2-基氨基甲酸酯衍生物及1，1，1-三氟-4-羟基丁-2-基氨基甲酸酯衍生物 |
| BR112019014688A2 (pt) | 2017-01-20 | 2020-02-18 | Pfizer Inc. | Derivados de carbamato de 1,1,1-trifluoro-3-hidroxipropan-2-il como inibidores de magl |
| EP3571202B1 (en) * | 2017-01-23 | 2021-06-30 | Pfizer Inc. | Heterocyclic spiro compounds as magl inhibitors |
-
2018
- 2018-01-08 BR BR112019014688-1A patent/BR112019014688A2/pt not_active Application Discontinuation
- 2018-01-08 KR KR1020197023870A patent/KR20190104405A/ko not_active Withdrawn
- 2018-01-08 MX MX2019008626A patent/MX2019008626A/es unknown
- 2018-01-08 CA CA3050625A patent/CA3050625C/en not_active Expired - Fee Related
- 2018-01-08 EP EP18703621.5A patent/EP3571191A1/en not_active Withdrawn
- 2018-01-08 CN CN201880013075.XA patent/CN110382479A/zh active Pending
- 2018-01-08 RU RU2019122800A patent/RU2720203C1/ru active
- 2018-01-08 WO PCT/IB2018/050103 patent/WO2018134695A1/en not_active Ceased
- 2018-01-08 AU AU2018208846A patent/AU2018208846A1/en not_active Abandoned
- 2018-01-08 JP JP2019538407A patent/JP2020506899A/ja not_active Withdrawn
- 2018-01-08 SG SG11201906417RA patent/SG11201906417RA/en unknown
- 2018-01-17 TW TW107101658A patent/TWI660946B/zh not_active IP Right Cessation
- 2018-01-19 US US15/874,987 patent/US10329308B2/en active Active
-
2019
- 2019-05-23 US US16/420,544 patent/US10626125B2/en active Active
- 2019-07-07 IL IL267899A patent/IL267899A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020506903A5 (enExample) | ||
| JP6982376B2 (ja) | Ｒｏｒガンマ調節物質としての置換型テトラヒドロキノリン化合物 | |
| JP2019526582A5 (enExample) | ||
| TWI583681B (zh) | 胺基嘧啶基化合物 | |
| AU2013339167B2 (en) | Novel amine derivative or salt thereof | |
| US11584732B2 (en) | Methods of treatment using 4-(3-cyanophenyl)-6-pyridinylpyrimidine mGlu5 modulators | |
| CN110573501A (zh) | Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途 | |
| JP2018534326A5 (enExample) | ||
| IL235051A (en) | A heterocyclic compound containing nitrogen or its salt | |
| US20140073620A1 (en) | Vegfr3 inhibitors | |
| CA2588278A1 (en) | Anthranilamide pyridinureas as vascular endothelial growth factor (vegf)receptor kinase inhibitors | |
| JP2009518444A (ja) | ケモカイン受容体のピリジニルスルホンアミドモジュレーター | |
| JP2007507540A (ja) | タンパク質キナーゼ阻害剤としての化合物および組成物 | |
| CN116514728A (zh) | 一种喹唑啉衍生物及其用途 | |
| CN119039379B (zh) | 一种蛋白降解靶向嵌合体分子及其应用 | |
| KR20070085609A (ko) | 혈관 내피 성장 인자 (ｖｅｇｆ) 수용체 키나제 억제제로서니코틴아미드 피리딘우레아 | |
| JP2025514385A (ja) | トリプタントリン誘導体およびその使用 | |
| NZ791931B2 (en) | Fused bicyclic sgc stimulators | |
| HK1241857B (zh) | 作为jak抑制剂的氨基嘧啶基化合物 | |
| OA18225A (en) | Aminopyrimidinyl compounds as Jak inhibitors. | |
| HK1224662B (en) | 4-(3-cyanophenyl)-6-pyridinylpyrimidine mglu5 modulators | |
| HK1224662A1 (en) | 4-(3-cyanophenyl)-6-pyridinylpyrimidine mglu5 modulators |